Сorrelation between age and the intensity of the post-vaccination humoral immune response in individuals passed COVID-19

Abstract

Introduction. Despite widespread vaccination against COVID-19 worldwide, the epidemiological situation remains insufficient. The appearance of mutant forms of SARS-CoV-2 with increased virulence causes new waves of COVID-19 morbidity. The virus variability can cause the reduction of the vaccination effectiveness. In this regard, it is important to study the dynamics of post-vaccination immunity, its features in various population groups, as well as the relationship between post-infectious and post-vaccination immunity. The study continues a series of researches of the features of SARS-CoV-2-specific immunity in COVID-19 convalescents and recipients of the «Sputnik V» vaccine.

The aim of the study – assessment of the intensity of the SARS-CoV-2-specific immune response in different age groups of people passed COVID-19 and subsequently vaccinated with «Sputnik V».

Material and methods. With the help of EIA, the level of IgG antibodies to S-antigen and N-antigen of SARS-CoV-2 was studied in 155 samples of blood sera of individuals (men and women) aged 18 to 70 years who passed COVID-19 and after 6 month of recovery underwent a full course of vaccination with «Sputnik V». Samples from individuals of the following age groups were examined: from 18 to 35, from 35 to 45, from 45 to 55, from 55 to 65, from 65 to 70 years.

Results. In all the examined age groups of individuals passed COVID-19 and then vaccinated with «Sputnik V», there was a high level of IgG antibodies to SARS-CoV-2 S-protein (positivity coefficient 8.1 and higher). The level of IgG antibodies to the N-protein in more than half of the cases was lower than positive values among all the subjects.

Conclusion. The study showed that individuals passed COVID-19 and then vaccinated with «Sputnik V», regardless of age, have intense post-vaccination humoral immunity.

Keywords:COVID-19; SARS-CoV-2; antibodies; post-vaccination immunity

For citation: Andreev A.I., Andreev I.V., Nechay K.O., Esaulova D.R., Baklakova O.S., Vechorko V.I., Shilovskiy I.P., Kofiadi I.A, Gudima G.O., Martynov A.I., Smirnov V.V., Kudlay D.A., Khaitov M.R. Сorrelation between age and the intensity of the post-vaccination humoral immune response in individuals passed COVID-19. Immunologiya. 2022; 43 (5): 583–92. DOI: https://doi.org/10.33029/0206-4952-2022-43-5-583-592 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. Authors declare no conflict of interests.

Authors’ contribution. Authors contributed equally to the writing of the article.

References

1. Listings of WHO’s response to COVID-19. URL: https://www.who.int/ru/news/item/29-06-2020-covidtimeline (in Russian)

2. Pashenkov M.V., Khaitov M.R. Immune response against epidemic coronaviruses. Immunologiya. 2020; 41 (1): 5–18. DOI: https://www.doi.org/10.33029/0206-4952-2020-41-1-5-18 (in Russian)

3. Boldyreva M.N. SARS-CoV-2 virus and other epidemic coronaviruses: pathogenetic and genetic factors for the development of infections. Immunologiya. 2019; 41 (3): 197–205. DOI: https://www.doi.org/10.33029/0206-4952-2020-41-3-197-205 (in Russian)

4. URL: https://www.rospotrebnadzor.ru/files/news2/2022/09/03.09.2022

5. Kozlov V.A., Tikhonova E.P., Savchenko A.A., Kudryavtsev I.V., Andronova N.V., Anisimova E.N., Golovkin A.S., Demina D.V., Zdzitovetsky D.E., Kalinina Y.S., Kasparov E.V., Kozlov I.G., Korsunsky I.A., Kudlay D.A., Kuzmina T.Yu., Minoranskaya N.S., Prodeus A.P., Starikova E.A., Cherdantsev D.V., Chesnokov A.B., P.A. Gear, A.G. Borisov. Clinical immunology. A practical guide for infectious diseases. Krasnoyarsk: Polikor, 2021. 563 p.

6. Komissarov A.A., Dolzhikova I.V., Efimov G.A., Logunov D.Y., Mityaeva O., Molodtsov I.A., Naigovzina N.B., Peshkova I.O., Shcheblyakov D.V., Volchkov P., Gintsburg A.L., Vasilieva E. Boosting of the SARS-CoV-2-Specific immune response after vaccination with single-dose Sputnik light vaccine. The Journal of Immunology. 2022; 208: 1139–45. DOI: https://doi.org/10.4049/jimmunol.2101052

7. Andreev I.V., Nechay K.O., Andreev A.I., Zubaryova A.P., Esaulova D.R., Alenova A.M., Nikolaeva I.A., Chernyavskaya O.P., Lomonosov K.S., Shulzhenko A.E., Kurbacheva O.M., Latysheva E.A., Shartanova N.V., Nazarova E.V., Romanova L.V., Cherchenko N.G., Smirnov V.V., Averkov O.V., Martynov A.I., Vechorko V.I., Gudima G.O., Kudlay D.A., Khaitov M.R., Khaitov R.M. Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection. Immunologiya. 2022; 43 (1): 18–32. DOI: https://doi.org/10.33029/0206-4952-2022-43-1-18-32 (in Russian)

8. Zakurskaya V.Ya., Sizyakina L.P., Kharitonova M.V., Shlyk S.V. Dynamics of specific humoral response in COVID-19 patients. Immunologiya. 2022; 43 (1): 71–7. DOI: https://doi.org/10.33029/0206-4952-2022-43-1-71-77 (in Russian)

9. Wheeler S.E., Shurin G.V., Yost M., Anderson A., Pinto L., Wells A., Shurin M.R. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. MicrobiolSpectr. 2021; 9: e00341-21. DOI: https://doi.org/10.1128/Spectrum.00341-21

10. Zaballa M-E., Perez-Saez J., de Mestral C., Pullen N., Lamour J., Turelli P., Raclot C., Baysson H., Pennacchio F., Villers J., Duc J., Richard V., Dumont R., Semaani C., Loizeau A.J., Graindorge C., Lorthe E., Balavoine J-F., Pittet D., Schibler M., Vuilleumier N., Chappuis F., Kherad O., Azman A.S., Posfay-Barbe K.M., Kaiser L., Trono D., Stringhini S., Guessous I. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland. medRxiv. 2022. 07. 27. 22278126. DOI: https://doi.org/10.1101/2022.07.27.22278126

11. Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 16 (18.08.2021)» (approved by the Ministry of Health of the Russian Federation). 2021, 249 р. URL: ВМР_COVID-19_V16.pdf (minzdrav.gov.ru) (in Russian)

12. Briko N.I., Zueva L.P., Pokrovskiy V.I. Epidemiologiya: textbook in two volumes. T. I. Мoscow: ООО «Medical News Agency», 2012. 768 р. ISBN: 5-89481. (in Russian)

13. Gushchin V.A., Dolzhikova I.V., Shchetinin A.M., Odintsova A.S., Siniavin A.E., Nikiforova M.A., Pochtovyi A.A., Shidlovskaya E.V., Kuznetsova N.A., Burgasova O.A., Kolobukhina L.V., Iliukhina A.A., Kovyrshina A.V., Botikov A.G., Kuzina A.V., Grousova D.M., Tukhvatulin A.I., Shcheblyakov D.V., Zubkova O.V., Karpova O.V., Voronina O.L., Ryzhova N.N., Aksenova E.I., Kunda M.S., Lioznov D.A., Danilenko D.M., Komissarov A.B., Tkachuck A.P., Logunov D.Y., Gintsburg A.L. Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines 2021; 9: 779. DOI: https://doi.org/10.3390/vaccines9070779

14. Ikegame S., Siddiquey M., Hung C.T., Haas G., Brambilla L., Oguntuyo K.Y., Kowdle S., Chiu H. P., Stevens C. S., Vilardo A. E., Edelstein A., Perandones C., Kamil J. P., Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature communications. 2021; 12 (1): 4598. DOI: https://doi.org/10.1038/s41467-021-24909-9

15. Nogrady B. Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature. 2021; 595 (7867): 339–40. DOI: https://doi.org/10.1038/d41586-021-01813-2

16. Gudima G.O., Khaitov R.M., Kudlay D.A., Khaitov M.R. Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunologiya. 2021; 42 (3): 198–210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210 (in Russian)

17. Lapa D., Grousova D.M., Matusali G., Meschi S., Colavita F., Bettini A., Gramigna G., Francalancia M., Garbuglia A.R., Girardi E., Puro V., Antinori A., Kovyrshina A.V., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Logunov D.Y., Naroditsky B.S., Vaia F., Gintsburg A.L. Retention of neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals. medRxiv. 2022: 22269335. DOI: https://doi.org/10.1101/2022.01.15.22269335

18. Guirakhoo F., Wang S., Yi Wang C., Kuo H.-K., Peng W.-J., Liu H., Wang L., Johnson M., Hunt A., Hu M. M., Monath T.P., Rumyantsev A., Goldblatt D. High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination. bioRxiv. 2022. DOI: https://doi.org/10.1101/2022.03.18.484436

19. Byazrova M.G., Astakhova E.A., Minnegalieva A.R., Prilipov A.G., Gorchakov A.A., Filatov A.V. Anti-Ad26 humoral immunity does not compromise neutralizing antibody responses following Ad26-based booster vaccination with Gam-COVID-Vac. Res Square. 2022. DOI: https://doi.org/10.21203/rs.3.rs-1649181/v1

20. Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., Scobie H.M., Moulia D., Markowitz L.E., Wharton M., McNally V.V., Romero J.R., Talbot H.K., Lee G.M., Daley M.F., Oliver S.E. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices – United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 (27): 977–82. DOI: https://doi.org/10.15585/mmwr.mm7027e2

21. Li M., Yuan J., Lv G., Brown J., Jiang X., Lu Z.K. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med. 2021; 11 (11): 1106. DOI: https://doi.org/10.3390/jpm11111106

22. Sukmarova Z.N., Ovchinnikov Yu.V., Gudima G.O., Ibragimova F.M., Afonina O.V., Machkalyan K.E. Hyperechogenic signal from the pericardium after vaccination against SARS-CoV-2. Infectious diseases. 2021; 19 (4): 43–50. DOI: https://doi.org/10.20953/1729-9225-2021-4-43-50 (in Russian)

23. DiGiulio M.B., Arbab R., Driscoll K. P., et al. COVID-19 infection may not produce lasting immunity in non-vaccinated young adults: a retrospective review of COVID-19 antibody data. Cureus. 2022; 14 (3): e23698. DOI: https://doi.org/10.7759/cureus.23698

24. CDC COVID data tracker. (2021). URL: https://covid.cdc.gov/covid-data-tracker (in Russian)

25. Long Q.X., Liu B.Z., Deng H.J., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26: 845–8. DOI: https://doi.org/10.1038/s41591-020-0897-1

26. Edridge A.W., Kaczorowska J., Hoste A.C., et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020; 26: 1691–3. DOI: https://doi.org/10.1038/s41591-020-1083-1

27. Robbiani D.F., Gaebler C., Muecksch F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584: 437–42. DOI: https://doi.org/10.1038/s41586-020-2456-9

28. Seow J., Graham C., Merrick B., et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020; 5: 1598–607. DOI: https://doi.org/10.1038/s41564-020-00813-8

29. Rydyznski-Moderbacher C., Ramirez S.I., Dan J.M., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020; 183: 996–1012.e19. DOI: https://doi.org/10.1016/j.cell.2020.09.038

30. Astakhova E.A., Byazrova M.G., Milyaev S.M., Sukhova M.M., Mikhailov A.A., Morozov A.A., Prilipov A.G., Filatov A.V. Flow cytometric assay for the detection of anti-SARS-CoV-2 Spike antibodies in serum of vaccinated volunteers. Immunologiya. 2022; 43 (4): 447–57. DOI: https://doi.org/10.33029/0206-4952-2022-43-4-447-457 (in Russian)

31. Byazrova M., Yusubalieva G., Spiridonova A., Efimov G., Mazurov D., Baranov K., Baklaushev V., Filatov A. Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19. Clin Transl Immunology. 2021; 10 (2): e1245. DOI: https://doi.org/10.1002/cti2.1245

32. Byazrova M.G., Kulemzin S.V., Astakhova E.A., Belovezhets T.N., Efimov G.A., Chikaev A.N., Kolotygin I.O., Gorchakov A.A., Taranin A.V., Filatov A.V. Memory B cells induced by Sputnik V vaccination produce SARS-CoV-2 neutralizing antibodies upon ex vivo restimulation. Front Immunol. 2022; 13: 840707. DOI: https://doi.org/10.3389/fimmu.2022.840707

33. Astakhova E.A., Byazrova M.G., Yusubalieva G.M., Kulemzin S.V., Kruglova N.A., Prilipov A.G., Baklaushev V.P., Gorchakov A.A., Taranin A.V., Filatov A.V. Functional profiling of in vitro reactivated memory B cells following natural SARS-CoV-2 infection and Gam-COVID-Vac vaccination. Cells. 2022; 11 (13): 1991. DOI: https://doi.org/10.3390/cells11131991

34. Baack B.N., Abad N., Yankey D., et al. COVID-19 vaccination coverage and intent among adults aged 18–39 years – United States, March-May 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 928–33. DOI: https://doi.org/10.15585/mmwr.mm7025e2

35. Bergeri I., Whelan M., Ware H., Subissi L., Nardone A., Lewis H.C., et al. Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Dec 2021. medRxiv. 2022. DOI: https://doi.org/10.1101/2021.12.14.21267791

36. Bekliz M., Adea K., Vetter P. et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat Commun. 2022; 13: 3840. DOI: https://doi.org/10.1038/s41467-022-31556-1

37. Eggink D. Andeweg S.P., Vennema H., et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro. Surveill. 2022; 27 (4). DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.4.2101196

38. Torresi J., Edeling M.A., Nolan T., Godfrey D.I. A complementary union of SARS-CoV2 natural and vaccine induced immune responses. Front. Immunol. 2022; 13: 914167. 2022. DOI: https://doi.org/10.3389/fimmu.2022.914167

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»